FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation

Jan.07.2025
FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation
FDA releases finalized guidelines on tobacco product analysis testing methods, providing manufacturers with support for regulatory submissions.

On January 6, the U.S. Food and Drug Administration (FDA) released the final version of the "Validation and Confirmation of Tobacco Product Analysis Methods" guidance, providing information and recommendations for tobacco manufacturers to support their submissions.


This guide provides detailed instructions for manufacturers on how to submit verified and validated data on analysis procedures and testing methods to the FDA for use in submissions including premarket tobacco product applications, substantial equivalence reports, and modified risk tobacco product applications.


Before being able to legally sell new tobacco products or modified risk tobacco products in the United States, companies must first submit an application to the FDA and receive approval. These applications typically require data and information to support the analytical methods used for testing tobacco products, and this guideline provides manufacturers and laboratories with scientifically sound information organization and presentation methods.


The principles described in this guide can also be applied to the writing of reports on harmful and potentially harmful constituents data required by tobacco product manufacturers and importers.


The draft version of this guide was released in 2021, allowing the public to provide feedback on the content. After considering this feedback, the FDA made adjustments to the final version of the guide, including updating the definition of "tobacco products" to include non-tobacco nicotine, adjusting the content to reflect the final PMTA and SE regulations, and updating and adding definitions for multiple terms. The final version of the guide also includes updated examples of alternative validation methods.


These suggestions are not legally binding and do not create legal obligations. In addition, the FDA acknowledges that there may be alternative validation procedures, such as statistical testing, that differ from the recommendations in this guide.


For applicants looking to introduce new tobacco products into the market, the FDA promises to continue providing information and resource support, including this recently released guide. The FDA has already issued regulations such as the PMTA final rule and regularly posts additional resources on its website and social media, such as application tips and webinars.


Compliance experts and consultants have provided the following analysis of the guidelines.


The U.S. FDA has issued this guide to provide tobacco manufacturers with guidance on conducting scientific validation and confirmation of analytical testing methods when submitting PMTA (premarket tobacco product application), SE (substantial equivalence application), and MRTPA (modified risk tobacco product application). This guide focuses on analytical testing of tobacco product ingredients, components, and additives, as well as issues related to chemical stability testing of finished tobacco products. It can also be used to guide testing and analysis of harmful and potentially harmful constituents (HPHC) in finished tobacco products, as well as other smoke or aerosol emissions. The guide aims to assist tobacco product manufacturers and analytical laboratories in collecting and presenting scientifically valid data and information to support analytical methods for submission to regulatory authorities for finished tobacco products. The recommendations in this guide will help the FDA better understand and evaluate the reliability of the data provided in regulatory submissions.


Click to read the final version of the guidelines for the validation and confirmation of analytical methods for tobacco products.


Readers are welcome to leave comments and get in touch with 2Firsts. Please contact: info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Philip Morris International Opens IQOS Flagship Boutique in the Philippines, Featuring an IQOS Scent Experience Zone
Philip Morris International Opens IQOS Flagship Boutique in the Philippines, Featuring an IQOS Scent Experience Zone
PMFTC, the Philippine affiliate of Philip Morris International (PMI), opened an IQOS flagship boutique on December 19 in the Ayala business district of Makati City, the Philippines. Positioned as a multi-sensory, immersive retail space, the store is designed for legal-aged nicotine users. It features the Philippines’ first IQOS Scent Experience zone and also showcases the upcoming IQOS x ISABEL collaboration.
Dec.29 by 2FIRSTS.ai
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia’s Ministry of Health said it conducted 25,643 enforcement operations involving inspections of 496,247 premises nationwide as of Nov.
Jan.09 by 2FIRSTS.ai
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over  USD 156,333 in seven-district operation
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over USD 156,333 in seven-district operation
In Sabah, Malaysia’s General Operations Force (GOF) seized thousands of e-cigarette devices, vapes and e-liquids worth more than RM635,000 and detained 23 people during a simultaneous integrated operation across seven districts.
Jan.19 by 2FIRSTS.ai
Kentucky lawmaker proposes directing Juul settlement funds to youth vaping prevention
Kentucky lawmaker proposes directing Juul settlement funds to youth vaping prevention
A Kentucky state senator has filed Senate Bill 74 to steer settlement money the Commonwealth received from vaping manufacturer Juul Labs into youth vaping prevention and cessation efforts.
Jan.14 by 2FIRSTS.ai
Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky to issue provisional state licenses to tobacco, nicotine and vapor retailers who applied before Jan. 1, 2026
Kentucky will issue provisional state licenses to tobacco, nicotine and vapor product retailers that applied for a license with the Department of Alcoholic Beverage Control (ABC) before Jan. 1, 2026.
Dec.31 by 2FIRSTS.ai